Singapore Exchange Ltd (SGX) is amending its initial public offering (IPO) rules to clarify that life science companies seeking to list on its mainboard exchange do not need to be revenue-generating.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
